Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (357)	8/16/1999 12:28:00 PM
From: Pseudo Biologist	Respond to of 1475

Thanks Rick. I think the main point I missed in my question is that pig-human (or ape) differ in a lot more than the two or three markers of the mouse studies of Sykes et al. This adhesion issue is probably just one of many that one has to worry about. Bottom line, one cannot assign a "product-based" value to XenoMune at this stage, as you rightly point out. PB

To: scaram(o)uche who wrote (357)	8/16/1999 10:02:00 PM
From: LLCF	Read Replies (1) \| Respond to of 1475

BTRN goes to town: Monday August 16, 4:31 pm Eastern Time Company Press Release BioTransplant Selected as One of 25 Companies Worldwide to Participate in Discovery Expo '99, August 19th in Chicago CHICAGO--(BUSINESS WIRE)--Aug. 16, 1999--BioTransplant Incorporated (Nasdaq: BTRN - news) will be among 25 growth companies to gather August 19th at Discovery Expo '99 to meet fund managers, analysts, stockbrokers and investors at The Midland Hotel. The Company, based in Charlestown, Mass., is developing pharmaceuticals and systems which are designed to re-educate the body's immune system to accept foreign cells, tissues and organs, creating potentially valuable new treatments for organ transplantation and cancers. BioTransplant's lead product, MEDI-507, is currently in multiple Phase II trials for treatment of graft-versus-host disease (GvHD), an often fatal outcome of bone marrow transplants. MEDI-507 is being developed in collaboration with MedImmune, Inc. The Company's AlloMune(TM) Systems, for human organ transplantation and blood cell cancers, are scheduled to begin initial human testing in 1999. The Company's XenoMune(TM) System, a system for cross-species organ transplantation, is in preclinical testing. BioTransplant has corporate collaborations with MedImmune and Novartis Pharma AG, as well as a range of scientific collaborators, including the Massachusetts General Hospital (MGH). BioTransplant Incorporated utilizes its proprietary technologies in re-educating the body's immune responses to allow tolerance of foreign cells, tissues and organs. Based on this ImmunoCognance(TM) technology, the Company is developing a portfolio of products designed to treat a range of medical conditions, including organ and tissue transplantation, cancer and autoimmune disease, for which current therapies are inadequate. BioTransplant's products are intended to induce long-term functional transplantation tolerance in humans, increase the therapeutic benefit of bone marrow transplants, and reduce or eliminate the need for lifelong immunosuppressive therapy. The Expo brings together undiscovered companies with high-profile growth fund managers, analysts, stockbrokers and sophisticated investors in a one-day event. These key players will have a chance to become acquainted with the products, top executives and future outlook of participating Nasdaq and OTC Bulletin Board listed firms whose stock represents opportunities for appreciation. For more information on attending, visit www.w3otc.com/tirweb/expo99/at-summer-99-c.htm, E-mail w3otc@w3otc.com, or call 949-724-0444. For more information on BioTransplant visit www.biotransplant.com